Location History:
- Berlin, DE (1999)
- Bärenklau, DE (2004)
Company Filing History:
Years Active: 1999-2004
Title: Albert Radlmaier: Innovator in Androgen Deficiency Treatment
Introduction
Albert Radlmaier is a notable inventor based in Bärenklau, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of androgen deficiency in men. With a total of two patents to his name, Radlmaier's work focuses on innovative combinations of existing compounds to enhance therapeutic outcomes.
Latest Patents
Radlmaier's latest patents include a groundbreaking invention that combines dehydroepiandrosterone (DHEA) with aromatase inhibitors. This combination is designed to produce a medicament for treating both relative and absolute androgen deficiency in men. The invention emphasizes the use of selective aromatase inhibitors such as atamestan, formestan, pentrozol, aramidex, fadrozol, CGS 20267, and vorozol. This innovative approach aims to improve the quality of life for men suffering from androgen deficiency.
Career Highlights
Throughout his career, Radlmaier has been associated with Schering Aktiengesellschaft, a prominent company in the pharmaceutical industry. His work has contributed to the development of effective treatments that address critical health issues related to hormone deficiencies.
Collaborations
Radlmaier has collaborated with esteemed colleagues such as Friedmund Neumann and Ursula-Friederike Habenicht. These partnerships have fostered a collaborative environment that encourages innovation and the advancement of medical science.
Conclusion
Albert Radlmaier's contributions to the field of medicine, particularly in the treatment of androgen deficiency, highlight his role as an influential inventor. His innovative patents and collaborations reflect a commitment to improving health outcomes for men.